More about Dr. Lal PathLabs Limited
Fundamentals for Dr. Lal PathLabs Limited
Regulatory Filings for Dr. Lal PathLabs Limited
From Cost Center to Strategic Core: The Top 10 Trends Transforming Finance in 2026
CFOs Seize the Tech Purse Strings: How 2026 Budgets Are Fueling the AI Transformation
From Agentic AI to Tokenized Assets: The Fintech Trends Reshaping Financial Services
Forex Focus: How a Weakening Indian Rupee Could Reshape Markets in Q1 2026
Fundamentals for Dr. Lal PathLabs Limited
Business Operations:
Sector: HealthcareIndustry: Diagnostics & Research
Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers training programs. The company was founded in 1949 and is based in Gurugram, India.
Revenue projections:
The projected decline in LALPATHLAB's revenues compared to last year is expected to make investors cautious. A drop in revenue often has a direct negative effect on the company's bottom line, signaling potential challenges that could undermine investor confidence and reduce overall profitability.
Financial Ratios:
| currentRatio | 0.00000 |
|---|---|
| forwardPE | 39.57900 |
| debtToEquity | 6.44100 |
| earningsGrowth | -0.06600 |
| revenueGrowth | 0.10600 |
| grossMargins | 0.58503 |
| operatingMargins | 0.20794 |
| trailingEps | 31.69000 |
| forwardEps | 35.43041 |
LALPATHLAB's low growth in both earnings and revenue signals a potential profit decline. This could be a sign of financial trouble, suggesting that the company's profitability might shrink in the near future.
Positive gross and operating margins for LALPATHLAB suggest that the company is operating profitably. These margins highlight LALPATHLAB's efficiency in managing costs while maintaining healthy revenue streams, contributing to its overall financial strength.
LALPATHLAB's forward EPS exceeding its trailing EPS means that the company is expected to increase profitability in the current financial year. This reflects improved earnings potential, signaling that LALPATHLAB is likely to outperform its previous year's financial performance.
Price projections:
LALPATHLAB's price projections have been revised downward gradually, indicating that analysts are tempering their expectations. This downward shift suggests a more cautious outlook on the company's growth prospects.
Insider Transactions:
LALPATHLAB experienced 39 selling transactions, with market price of 2992.944864908854.1 purchases of LALPATHLAB stock were recorded, with market price of 3308.5 per share.No clear trend can be drawn from the insider transactions, leaving the company's next steps and outlook uncertain from this data alone.
Recommendation changes over time:
Analysts have shown a buy bias for Dr. Lal PathLabs Limited, marking it as a favorable investment option. This could inspire investors to see Dr. Lal PathLabs Limited as a strong place to park their money, given the positive outlook and growth potential associated with the stock in recent evaluations.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
Understanding Divergent House Price Movements Worldwide
The 2026 Tariff Tipping Point: When Trade Policy Reaches the Consumer
From Caracas to Commodities: The Market Impact of U.S.–China Friction